

# Human Immunodeficiency Virus Type 1 Two-Long Terminal Repeat Circles: A Subject for Debate

Isabel Olivares, María Pernas, Concepción Casado and Cecilio López-Galindez

Department of Molecular Virology, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

## Abstract

**HIV-1 infections are characterized by the integration of the reverse transcribed genomic RNA into the host chromosomes making up the provirus. In addition to the integrated proviral DNA, there are other forms of linear and circular unintegrated viral DNA in HIV-1-infected cells. One of these forms, known as two-long terminal repeat circles, has been extensively studied and characterized both in *in vitro* infected cells and in cells from patients. Detection of two-long terminal repeat circles has been proposed as a marker of antiretroviral treatment efficacy or ongoing replication in patients with undetectable viral load. But not all authors agree with this use because of the uncertainty about the lifespan of the two-long terminal repeat circles. We review the major studies estimating the half-life of the two-long terminal repeat circles as well as those proposing its detection as a marker of ongoing replication or therapeutic efficacy. We also review the characteristic of these circular forms and the difficulties in its detection and quantification. The variety of approaches and methods used in the two-long terminal repeat quantification as well as the low reliability of some methods make the comparison between results difficult. We conclude that it is not possible to draw a clear supposition about the lifespan of two-long terminal repeat circles and consequently they should not be used as a marker of ongoing replication without a careful analysis of the methods and results.** (AIDS Rev. 2016;18:23-31)

Corresponding author: Isabel Olivares, [iolivar@isciii.es](mailto:iolivar@isciii.es)

## Key words

**HIV-1. Virus replication. Viral DNA. Circular DNA. HIV-1 LTR.**

## Introduction

The most characteristic step of the replicative cycle of retrovirus is the conversion of the viral genomic RNA to cDNA (a linear double-stranded DNA) carried out by the viral reverse transcriptase. The cDNA is transported into the nucleus in a pre-integration complex and integrated into the host cell genome by the action of the viral integrase<sup>1</sup>. This integrated viral cDNA is designated

proviral DNA. In addition to the proviral DNA, cells infected by retrovirus contain several forms of unintegrated viral DNA, mainly linear DNA, two-long terminal repeat (2-LTR) circles, and 1-LTR circles (Fig. 1).

The existence of unintegrated DNAs in cells infected by retroviruses was first described in cells infected by avian sarcoma virus<sup>2</sup> or Moloney murine leukemia virus<sup>3</sup>. The first characterization of circular unintegrated DNA with 1-LTR or 2-LTR was carried out in the nuclear DNA from cells infected by mouse mammary tumor virus and avian sarcoma virus<sup>4,5</sup>.

Unintegrated HIV-1 DNA was first identified in CEM and H9 infected cells or in peripheral blood mononuclear cells (PBMC) infected *in vitro*<sup>6,7</sup>. The characterization of the 1-LTR and 2-LTR forms was performed in CEM and U937 cells infected by HIV-1<sup>7,8</sup>. In HIV-1-infected patients, the presence of unintegrated DNA was

### Correspondence to:

Isabel Olivares  
Servicio de Virología Molecular  
Centro Nacional de Microbiología, Instituto de Salud Carlos III  
Majadahonda, Madrid, Spain  
E-mail: [iolivar@isciii.es](mailto:iolivar@isciii.es)

detected in activated PBMCs<sup>9</sup>, in resting CD4+ T-cells from lymph nodes or blood<sup>10</sup>, and in other cells such as tissue macrophages in the brain<sup>11</sup>.

Although the 2-LTR circles are the less abundant form of unintegrated viral DNA in infected cells<sup>8</sup>, they have become the most widely studied due to the difficulty of detection and quantification of the other unintegrated DNA forms.

In HIV-1 patients, much effort has been made in order to use the presence of 2-LTR circles as a prognostic marker of the infection<sup>12,13</sup>. The existence of 2-LTR circles in HIV-1 patients on long-term antiretroviral therapy is considered an evidence of recent viral replication<sup>12,14</sup>. This statement assumes that 2-LTR circles have a short lifespan, and thus their presence can only be caused by recent viral replication<sup>15,16</sup>. However, there is a great polemic in relation to the lifespan of 2-LTR circles because other authors think that 2-LTR circles can persist for a long time in cells<sup>17,18</sup>. The estimation of the 2-LTR circles half-life has been performed by different methods, making the comparison between studies difficult. Quantification of 2-LTR circles is especially problematic when the template concentration is low, as in the case of HIV-1-treated patients<sup>19</sup>. The aim of the review is to discuss the controversy about the lifespan of 2-LTR circles and of its use as a marker of ongoing replication in patients.

## Mechanisms of generation of circular viral DNA

All circular HIV DNAs are derived from the linear DNA that is made circular by different mechanisms<sup>20</sup>. The 2-LTR circles are formed by the joining, in the nucleus, of both ends of the linear DNA by cell ligases<sup>20-22</sup>. The formation of the 2-LTR circles seems to be related to the protection of the cells for the toxicity of the double-stranded ends of the unintegrated linear DNA. Indeed, the host cell non-homologous DNA end joining (NHEJ) pathway, which repairs double strand breaks, is involved in the 2-LTR circle formation<sup>23</sup>. Specifically, the NHEJ factors Ku protein, ligase 4, and XRCC4 have been implicated in this mechanism<sup>23</sup>.


It is generally assumed that 1-LTR circles are formed by recombination of the LTRs from the linear DNA, and a model for its formation based in *in vitro* experiments was proposed<sup>20</sup>. The 1-LTR circles could also arise from incomplete products from reverse transcription<sup>24</sup>. In fact, a significant proportion (about 10%) of the 1-LTR circles are formed in the cytoplasm, coincident with reverse transcription<sup>22</sup>. At present, why 1-LTR circles are formed is unknown, but the Rad50/Mre11/

NBS1 complex, also implicated in DNA repair, was involved in its formation<sup>25</sup>.

In cells infected by retroviruses, in addition to 2-LTR and 1-LTR circles, other circular forms with different size or with LTRs in an incorrect position are found. These irregular circles seem to be formed by autointegration<sup>8,21</sup>, that produces a diversity of forms like nicked inverted and subgenomic DNA circles (Fig. 1)<sup>21</sup>.

## Long terminal repeat circle junctions

The boundary between the two LTRs in 2-LTR circles is named circle junction. The linear DNA product of reverse transcription has a dinucleotide added at each LTR end (GT at the 3' and AC at the 5') relative to the RNA sequence (Fig. 1). For integration, the viral integrase deletes a GT dinucleotide at each 3' end of the linear DNA (endo-nucleotide cleavage known as 3' processing)<sup>26</sup>. In HIV-1, the blunt end ligation of both ends of linear DNA produce the junction sequence CAG-TACTG, where GT and AC are the dinucleotides added (Fig. 1). This sequence, named canonical junction sequence, is the most frequently found in 2-LTR circles. Circle junction sequences lacking some of these nucleotides are also found because of the circularization of total or partially processed linear DNA forms. Moreover, there are a variety of other junction sequences with insertions or deletions of diverse sizes or sequences coming from defective linear molecules unable to integrate<sup>27-30</sup> (Fig. 2). Insertions often contain a part of the primer binding site or the polypurine tract (ppt) sequence. This is understood to be caused by the RNase H failure in removing the tRNA primer from the minus strand DNA, or the ppt primer from the plus strand DNA during reverse transcription<sup>28,31</sup>. Indeed, mutations in the viral RNase H modifying the RNase activity increased the number of 2-LTR circle junctions with these insertions<sup>32</sup>. Junction sequences with bigger insertions containing fragments of other regions of the viral genome are also found because of autointegration<sup>21</sup> and they could be considered as a class of molecules distinct from the 2-LTR circles. Deletions in the junction sequence were explained by the degradation of viral DNA ends by host nucleases at one or both ends of the viral DNA before ligation<sup>29</sup>. The amount of canonical sequences is around 50-60% in *in vitro*-infected cells<sup>28,32</sup>, but in PBMCs from patients, the fraction of junction sequences with anomalous sequences is higher (66.0-87.5%)<sup>31,33</sup>. Figure 2 shows some examples of the several types of 2-LTR circle junction sequences, and the different mechanisms suggested for their formation.



**Figure 1.** Viral DNA forms in HIV-1-infected cells. The sequence of the dinucleotide added at each long terminal repeat end, which constitute the canonical junction sequence in 2-LTR circles, appears in linear DNA and 2-LTR circles. Position of the primers used for amplification of circular DNA forms is shown.  
LTR: long terminal repeat.

## Methods for the detection and quantification of two-long terminal repeat circles


The first descriptions of unintegrated retroviral DNA as well as the characterization of 1-LTR and 2-LTR circles were made by Southern blot analysis with DNA from retrovirus-infected cells. Fragments corresponding to 1-LTR and 2-LTR circles were identified by their migration in agarose gels and characterized by restriction endonucleases digestion<sup>4,6,7</sup>.

Since 1990, all studies aimed at the detection and quantification of unintegrated circular DNA, were performed by a specific polymerase chain reaction (PCR), using primers whose orientation permit only the amplification of the circular DNA<sup>34,35</sup>. Sometimes, PCR primers hybridizing in *gag* and *env* genes were used for the detection of both 1-LTR and 2-LTR circles<sup>15</sup> (Fig. 1). But these primers often produce false positive amplifications since they can amplify other DNA forms, as for example linear unintegrated or

proviral DNA<sup>36</sup>. A specific PCR for the detection of 2-LTR circles with primers hybridizing inside the LTR is more reliable. In theory, primers that span the 2-LTR circle junction can only amplify 2-LTR circles; however, the products obtained after amplification with these primers sometimes do not correspond to 2-LTR circles but to other DNA circles formed by autointegration<sup>20</sup> or to artifacts made during amplification<sup>37</sup>. Limited amounts of target DNA contribute to the generation of unspecific products during PCR<sup>38</sup>.

Quantification of 2-LTR circles has been performed by several techniques (Table 1); (i) specific PCR followed by Southern blot using an internal radioactive probe<sup>18,34,37</sup>, (ii) real-time quantitative PCR using fluorescent cyanine dyes<sup>35,38,39</sup>; (iii) real-time quantitative PCR using TaqMan probes<sup>40,41</sup>; and (iv) droplet digital PCR (ddPCR)<sup>19,42</sup>.

Real-time PCR techniques are the most widely used for 2-LTR circles quantification. They require for quantification of PCR products the development of a standard curve with known amounts of the amplicon per reaction.



**Figure 2.** Types of two-long terminal repeat circles junction sequences. One example of each type of known junction sequences is shown. Sequences were obtained from: (a) Hong, et al.<sup>28</sup>; (b) Jurriaans, et al.<sup>31</sup>; (c) Olivares, et al.<sup>71</sup>; and (d) Svarovskaia, et al.<sup>29</sup>. \*Bold letters mark the canonical dinucleotide junction sequence. Mechanisms proposed by the formation of each type are listed. Ppt: polypurine tract.

For this purpose, serial dilutions of a plasmid containing a DNA fragment with the canonical junction sequence of 2-LTR circles are usually employed. Optimization of the techniques using plasmid dilutions provides a good efficiency and reliability. However, amplification of 2-LTR circles from *in vitro* infected cells and from infected patients' PBMCs is affected by viral sequence variability, circle junction variability, the presence of different DNA forms in the same sample, and the low proportion of 2-LTR circles relative to total cellular DNA. Although conserved sequences are selected in the design of primers and probes for the 2-LTR circle-specific PCR, mutations and deletions in the 2-LTR circles can cause a poor annealing and an underestimation of the 2-LTR

circles. On the contrary, artifacts produced from the amplification of other DNA forms could lead to false positives and higher values. Indeed, in some quantitative PCR reactions, products were analyzed on agarose gels or submitted to sequence analysis to ensure their specificity<sup>18,40</sup>. All these problems are more evident when low amounts of 2-LTR circles exist, as in the case of treated patients. In studies comparing quantification of 2-LTR circles by real-time PCR and by ddPCR, a low reliability was obtained with values < 300 copies/million cells using real-time PCR. Droplet digital PCR resulted in a 20-fold increase in accuracy, suggesting that this technique could prove the most useful for 2-LTR circles quantification in cells from patients<sup>19</sup>. Moreover ddPCR

**Table 1. Methods for the detection and quantification of two-long terminal repeat circles**

| Method                                     | Detection   | DNA            | Specificity     | References   |
|--|---|----------------|-----------------|--|
| Real-time PCR                              | TaqMan probe  | Episomal*      | 2-LTR           | Sharkey, et al. <sup>40</sup> ; Brussel, et al. <sup>43</sup>    |
| Real-time PCR                              | TaqMan probe  | Total cellular | 2-LTR           | Butler, et al. <sup>17</sup> ; Gillim Ross, et al. <sup>47</sup> |
| Conventional single PCR                    | Southern blot<br>P <sup>32</sup> labeled probe      | Total cellular | 2-LTR           | Pierson, et al. <sup>18</sup>                                    |
| Real-time PCR                              | SYBR Gold   | Episomal†      | 2-LTR           | Teo, et al. <sup>35</sup>  |
| Real-time PCR                              | TaqMan probe  | Total nuclear  | 1-LTR and 2-LTR | Kelly, et al. <sup>44</sup>                                      |
| Conventional single PCR                    | Southern blot<br>Phosphatase alkaline labeled probe | Total cellular | 2-LTR           | Clarke, et al. <sup>51</sup>                                     |
| ddPCR                                      | TaqMan probe  | Total cellular | 2-LTR           | Hatano, et al. <sup>14</sup>                                     |
| Real-time PCR                              | SYBR green  | Episomal‡      | 2-LTR           | Casibianca, et al. <sup>75</sup>                                 |
| Pre-amplification and real-time nested PCR | TaqMan probe  | Cell lysates   | 2-LTR           | Vandergeeten, et al. <sup>76</sup>                               |
| ddPCR                                      | TaqMan probe  | Episomal*      | 2-LTR           | Malatinkova, et al. <sup>46</sup>                                |

\*Episomal DNA was obtained from cell pellet using QIAprep Miniprep Kit (Qiagen).

†Cell lysates were first digested with proteinase K. Episomal DNA was obtained using QIAprep Miniprep Kit and the remaining genomic DNA was removed by Plasmid-Safe DNase digestion.

‡Episomal DNA obtained from 5 µg of total cell DNA using QIAprep Miniprep Kit.

PCR: polymerase chain reaction; ddPCR: droplet digital PCR; LTR: long terminal repeat.

provides an absolute quantification of target sequences without relying on the use of standard curves<sup>19</sup>.

In addition to the PCR, another factor affecting the 2-LTR circles quantitation is the origin of the DNA used in the amplification. One of the most important problems for the 2-LTR circles amplification is the low rate of these forms among a large background of host cellular DNA. This low quantity requires the use in the PCR of a great amount of DNA, which can inhibit the PCR reaction<sup>19</sup>. Methods for the elimination of high molecular DNA, as the Hirt DNA extraction method, were used in 2-LTR characterization studies in order to increase the episomal concentration<sup>6-8,21,27</sup>. Also, plasmid DNA isolation methods that remove bacterial genomic DNA were employed for the separation of episomal DNA in *in vitro* and *ex vivo* studies<sup>35,39,40,43</sup>, whereas in other works, high molecular DNA was not removed<sup>18,19,44</sup>.

Although the recovery of 2-LTR circles DNA seems clearly enriched using plasmid isolation methods<sup>40</sup>, there are conflicting results regarding the efficacy of these methods to obtain 2-LTR circles. In a study comparing the impact of different extraction methods on the recovery of 2-LTR circles, bacterial plasmid extrac-

tion recovered only 10-20% of the 2-LTR circles DNA, whereas total DNA extraction achieved about 45% of the 2-LTR circles<sup>45</sup>. However, others authors found higher levels of recovery (1.9-fold) with plasmid extraction methods than with total DNA extraction<sup>46</sup>. A drawback of the bacterial plasmid extraction method is the wide variation observed in the isolation efficiency between experiments, making a normalization necessary<sup>46</sup>. Table 1 summarizes some of the differential characteristic of the methods used for the detection of 2-LTR circles.

## Lifespan of two-long terminal repeat circles

A great controversy about the lifespan of 2-LTR circles exists. On the one hand, 2-LTR circles have been proposed to have a short lifespan because they are degraded by cellular enzymes. On the other hand, 2-LTR circles could be as long lasting as other circular DNA forms. Several *in vitro* and *in vivo* studies, using different approaches and methods, have been performed for the resolution of this issue, but with discordant conclusions. The first studies were made in cell culture, measuring the decay of 2-LTR circles; in HIV-1-infected PBMC or

CEM cells a half-life of 16 days was estimated<sup>37</sup>. In another work, in favor of the lability of 2-LTR circles, MT-4 or Jurkat cells were infected with an HIV-1 isolate and after 24 hours a reverse transcriptase inhibitor was added to avoid further rounds of virus infection. In this experiment, a rapid decrease of 2-LTR circles in both cell types was observed<sup>40</sup>.

Two main papers have been published against the lability of 2-LTR circles<sup>17,18</sup>. In the first one, SUP-T1 cells were infected with HIV-1, adding a protease inhibitor to restrict viral replication to a single cycle; the decrease in 2-LTR circles correlated with the death of the infected cells and with the culture dilution<sup>17</sup>. In the second work, MT-2 cells were infected and after 48 hours cells were treated with indinavir; the decay of 2-LTR circles, cell death, and cell division were carefully measured, and the decay of the 2-LTR circles was very similar to the inverse of the doubling time of the cells, indicating that the dilution factor is responsible for the decay<sup>18</sup>. In order to exclude the dilution factor, *in vitro* experiments infecting monocyte-derived macrophages were performed because these cells do not divide. In Teo, et al.<sup>35</sup>, the half-life for 2-LTR circles was 19.2 hours, while in two similar studies using an integrase-defective virus, they did not find a decay of the 2-LTR circles after 21 days<sup>47</sup> or 30 days post-infection<sup>44</sup>.

Recently, the stability of 2-LTR circles was examined in primary naive CD4+ T-cells infected *in vitro* and cultured for a month. Since T-cell receptor excision circles (TREC) are accepted to be stable, the stability of 2-LTR circles was compared with the stability of TREC and with the integrated HIV DNA. In conditions where naive cells do not divide nor decrease viability, 2-LTR circles and TREC were stable for 30 days of culture, suggesting that both forms are stable<sup>48</sup>.

*In vivo* studies to investigate the lifespan of 2-LTR circles have often been made in HIV-1-infected patients after antiretroviral treatment. In PBMCs from four HIV-1-infected patients, after adjustments for antiretroviral treatment, Sharkey, et al.<sup>40</sup> found that decreases in plasma viral load were accompanied by a considerable decline in 2-LTR circle copy numbers, in contrast with a lower diminution of total viral DNA levels; the authors concluded that 2-LTR circles are labile *in vivo*. This result was supported by another study where in seven out of nine patients, after the beginning of antiretroviral treatment, viral load decrease correlated with a decrease of 2-LTR circles<sup>39</sup>. However, with a similar approach in 11 HIV-1 patients in whom antiviral treatment led to a rapid decrease in viral load, no decrease of 2-LTR circles was found<sup>43</sup>.

With a different approach, the lability of 2-LTR circles was evaluated in 11 patients after the initiation of treatment by comparing the emergence of the drug resistance mutation to lamivudine (M184V) in plasma RNA, episomal DNA, and proviral DNA. A complete replacement of the wild-type sequence with the M184V mutation was observed in the plasma viral RNA and in the episomal DNA, while proviral DNA remained wild-type. This result suggested that the wild-type 2-LTR circles were degraded<sup>49</sup>.

More recent studies calculated the half-life of 2-LTR circles *in vivo* by monitoring for 100 days after the beginning of treatment 2-LTR circles, integrated DNA, and total DNA levels<sup>41</sup>. The study was performed in two groups of HIV-1 patients with primary and chronic HIV-1 infection. Integrated and total DNA levels were greater in the chronic infection because they accumulated over time, while no differences in 2-LTR circle levels were observed between primary and chronic HIV-1 infection, suggesting that 2-LTR circles do not accumulate because of their lability. Moreover, consistent with the use of an integrase inhibitor, a rapid increase of 2-LTR circles was detected at the initiation of therapy; this increase was followed by a decay, with a half-life of about 25 days that supports the lability of this form. However, a slower second-phase decay was observed with a half-life of 169 days<sup>41</sup>. The same authors in a different study, analyzing several subsets of CD4+ T-cells after the start of therapy, estimated a half-life of the 2-LTR circles at around 12-52 weeks<sup>50</sup>.

In an interesting work studying the replication dynamic of the simian immunodeficiency virus (SIVmac) in macaques, it was possible to analyze several lymphoid tissues (spleen, mesenteric lymph nodes, peripheral lymph nodes, and thymus). In the peripheral blood cells, 2-LTR circles levels increased up to 28 days post-infection, but they disappeared at 42 days post-infection. However, at this time, high levels of 2-LTR circles were detected in lymphoid tissues. The difference between the levels of 2-LTR circles in different body compartments cautions against conclusions from *in vivo* experiments<sup>51</sup>.

The different approaches and methods used in all reviewed works make difficult the comparison between studies and could influence the different conclusions. Based in the analysis of all these studies, we cannot draw a clear conclusion about the lifespan of the 2-LTR circles.

### **Practical use of two-long terminal repeat circles detection in HIV-1-infected patients**

Two-LTR circle quantification was proposed as a marker of antiretroviral drug therapeutic efficacy<sup>13</sup>. In *in vitro* studies, after treatment of infected cells with antiretroviral

drugs acting on different steps of viral replication, a decrease of 2-LTR circles was observed<sup>52</sup>. *In vivo*, while total and integrated DNA levels were stable in a high proportion of patients during early stages of HAART, a rapid decrease of 2-LTR circles level was observed<sup>53</sup>. Puertas, et al.<sup>54</sup> supported the efficacy of maraviroc added to triple therapy because of a decline of 2-LTR circles.

*In vitro*, the integration block with integration-defective virus<sup>55</sup> or by treatment with integrase inhibitors lead to an increase in the 2-LTR circle levels<sup>29,56</sup>. This result is probably related to the fact that if integration is inhibited, there will be more DNA available for circularization. In patients treated with raltegravir, an increase of 2-LTR circle levels was observed soon after treatment; this increase was transient and followed by a decrease as a result of a decrease in viral replication<sup>12,14</sup>.

Some authors have questioned the use of 2-LTR circles as a marker of therapeutic efficacy<sup>43,57-59</sup>. Studies with patients after months on HAART or submitted to structured interruption of antiretroviral therapy found a low impact in 2-LTR circle levels<sup>43,57</sup>. Also, in patients treated with integrase inhibitors, no change in 2-LTR circle levels was observed<sup>58,59</sup>. Diverse criteria for the selection of HIV-1 patients as well as the type of treatment, previous treatments, or viremia can be responsible for the distinct results. Also, the different time of sample recovery and the techniques used for the quantification of 2-LTR circles can affect the results of the study.

A possible prognostic value of 2-LTR circle levels in HIV-1-infected patients was investigated since they were related to clinical progression, CD4+ T-cell levels, and plasma viremia<sup>9,37</sup>. However, no clear conclusion was reached<sup>60</sup>. Sequence analysis of episomal DNA was proposed for the prediction of the virus that rebound after therapy interruption since the viral rebound RNA sequence was phylogenetically related to the episomal but not to the proviral sequences present before treatment interruption<sup>61</sup>.

### **Long terminal repeat circles as a marker of ongoing replication**

The origin and the mechanisms responsible for the residual viremia in HIV-1-infected patients after prolonged HAART still remain unclear<sup>62</sup>. Since HIV-1 persists as a latent provirus in resting memory CD4+ T lymphocytes<sup>63</sup>, a first possibility was that residual viremia is the consequence of the reactivation of these cells. Some authors have questioned this origin<sup>64,65</sup> and they propose a low-level continuous viral replication in an unknown reservoir. Presence of 2-LTR circles in HIV-1

patients on long-term treatment has been often used to support the existence of ongoing replication<sup>15,16</sup>. More strong evidence of ongoing replication has been suggested by the transient increase in 2-LTR circle levels after drug intensification with raltegravir in patients previously treated with HAART<sup>12,14</sup>. For the explanation of the formation of 2-LTR circles in the presence and absence of raltegravir intensification, a mathematic model was developed<sup>66</sup>; this model was validated against patient data from the Buzon study<sup>12</sup>. According to this model, a transient increase in 2-LTR circle concentrations after raltegravir intensification is consistent with significant levels of efficient *de novo* infection cycles<sup>66</sup>.

The evidence of ongoing replication based in 2-LTR circle levels was criticized by others<sup>67</sup>. They claimed that the changes in 2-LTR circle levels after raltegravir intensification were not followed by changes in viral load, as would occur if treatment with raltegravir inhibited residual viral replication. Also, in a group of patients monitored for 10 years after HAART, a similar decay pattern of 2-LTR circles and total HIV-1 DNA was detected; this, along with the persistence of 2-LTR circles throughout the follow-up, suggests that 2-LTR circles may persist in long-lived cells and are not necessarily an indicator of ongoing HIV-1 replication<sup>68,69</sup>.

### **Research applications**

In spite of the conflict about the use of 2-LTR circles as a diagnostic or prognostic marker, its quantification and the analysis from junction sequence has been useful in many HIV-1 research studies. For example, mutations in the polypurine tract affecting HIV-1 replication<sup>70</sup> or mutations in the RNase H affecting its specificity<sup>32</sup> were characterized by analysis of the 2-LTR circles junction sequence. Also, in the exploration of the mechanism of action of the integrase inhibitors azido-containing  $\beta$ -diketo acid derivatives, analysis of the 2-LTR circle junction sequence was used<sup>29</sup>. Ongoing replication in a persistently HIV-1-infected cell line was evidenced by the existence of 2-LTR circles<sup>71</sup>.

In studies exploring the mechanisms responsible for the control of viremia in elite controllers, measurements of 2-LTR circles were also performed. These patients were found to have lower levels of integrated DNA and higher levels of 2-LTR circles compared to patients on HAART<sup>72</sup>. Due to this result, it was proposed that in elite controllers there was an integration inhibition. However, attempts to demonstrate this inhibition in *ex vivo* infection of PBMCs from elite controllers resulted in conflicting results<sup>72,73</sup>.

## Conclusions

Much effort has been made to understand the significance of unintegrated DNA forms in HIV-1-infected cells. Despite that 2-LTR forms are the less abundant of all unintegrated viral DNA, they have been the most widely studied<sup>8,63,74</sup>. This is because the characteristic junction sequence makes possible the use of a specific PCR for their detection, while the study of other unintegrated DNA forms by PCR produces false positives<sup>36</sup>.

Regarding the quantification of 2-LTR circles, the difficulty comes from the low proportion of these forms among the host cellular DNA background. In addition, viral sequence and circle junction variability with the presence of insertions and deletions makes a significant proportion of sequences undetectable. In spite of this, in *in vitro* infected cells there is enough unintegrated DNA to perform the detection and quantification, and the study of the junction sequences in 2-LTR circles has been fruitful in many HIV-1 research studies<sup>29,32,70,71</sup>.

In HIV-1-infected patients, there have been many attempts to relate the level of 2-LTR circles with different aspects of infection, such as the estimation of treatment efficacy, the detection of ongoing replication in treated patients, or as a prognostic marker of clinical evolution. But quantification of 2-LTR circles in samples of HIV-1-infected patients is more problematic than in *in vitro*-infected cultures since levels of 2-LTR circles in patient samples are often below 50 copies per million PBMCs<sup>12,14,53,72</sup>.

Most studies in which conclusions were drawn about the lifespan of 2-LTR circles and the existence or not of viral replication in treated patients were usually performed using real-time PCR for the quantification of 2-LTR circles. This technique does not produce reliable results at template concentrations below 300 copies per million cells, values that are frequent in treated patients<sup>19</sup>. Probably, the use of ddPCR could result in more reliable data, but so far this technique has been rarely used in these studies. Moreover, in a high proportion of studies, episomal DNA was extracted using the bacterial isolation plasmid methods before the diagnostic by PCR. These isolation methods showed a high variation in the efficiency of the recovery of 2-LTR circles and highlight the need for normalization<sup>46</sup>. But these extraction methods have been employed in many studies without an estimation of the recovery efficiency.

The description of all the problems associated with the methods for quantification of 2-LTR circles and the difficult comparison between studies (different methods, contradictory results, lifespan controversy, etc.) caution

against the use of 2-LTRs as a marker of ongoing replication in treated patients without a careful analysis of the methods and results.

## Declaration of interest

This work was supported by grants SAF 2010-17226 from MICIN Spain and FIS (PI 13/02269) from the Fondo de Investigaciones Sanitarias (ISCIII) and in part by the SPANISH AIDS Research Network RD12/0017/0036 that is included in Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011, Instituto de Salud Carlos III, Fondos FEDER.

## References

1. Coffin JM, Hughes SH, Varmus HE. *Retroviruses* Cold Spring Harbor (NY): Cold Spring Harbor Press. 1997.
2. Guntaka RV, Mahy BWJ, Bishop JM, Varmus HE. Ethidium-Bromide inhibits appearance of closed circular viral DNA and integration of virus-specific DNA in duck cells infected by avian-sarcoma virus. *Nature*. 1975;253:507-11.
3. Gianni AM, Smotkin D, Weinberg RA. Murine leukemia virus: detection of unintegrated double-stranded DNA forms of provirus. *Proc Natl Acad Sci USA*. 1975;72:447-51.
4. Shank PR, Hughes SH, Kung HJ, et al. Mapping unintegrated avian sarcoma virus DNA termini of linear DNA bear 300 nucleotides present once or twice in 2 species of circular DNA. *Cell*. 1978;15:1383-95.
5. Shank PR, Cohen JC, Varmus HE, Yamamoto KR, Ringold GM. Mapping of linear and circular forms of mouse mammary tumor virus DNA with restriction endonucleases: evidence for a large specific deletion occurring at high frequency during circularization. *Proc Natl Acad Sci USA*. 1978;75:2112-6.
6. Stevenson M, Meier C, Mann AM, Chapman N, Wasik A. Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. *Cell*. 1988;53:483-96.
7. Pauza CD, Galindo JE, Richman DD. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of Cem cells. *J Exper Med*. 1990;172:1035-42.
8. Pauza CD, Galindo J. Persistent human immunodeficiency virus type-1 infection of monoblastoid cells leads to accumulation of self-integrated viral DNA and to production of defective virions. *J Virol*. 1989;63:3700-7.
9. Panther LA, Coombs RW, Zeh JE, Collier AC, Corey L. Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: Association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. *J Acquir Immune Defic Syndr*. 1998;17:303-13.
10. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection. *Nature*. 1997;387:183-8.
11. Pang S, Koyanagi Y, Miles S, Wiley C, Vinters HV, Chen ISY. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. *Nature*. 1990;343:85-9.
12. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. *Nat Med*. 2010;16:460-5.
13. Donovan RM, Bush CE, Smereck SM, Baxa DM, Markowitz NP, Saravolatz LD. Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy. *J Infect Dis*. 1994;170:202-5.
14. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV Infection: A randomized, placebo-controlled trial. *J Infect Dis*. 2013;208:1436-42.
15. Hauber I, Harrer T, Low P, Schmitt M, Schwingel E, Hauber J. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads. *AIDS*. 2000;14:2619-21.
16. McDermott JL, Martin I, Ferrari D, et al. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. *J Clin Microbiol*. 2005;43:5272-4.
17. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. *J Virol*. 2002;76:3739-47.
18. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. *J Virol*. 2002;76:4138-44.
19. Strain MC, Lada SM, Luong T, et al. Highly precise measurement of HIV DNA by Droplet Digital PCR. *PLoS One*. 2013;8:e55943.

20. Farnet CM, Haseltine WA. Circularization of human immunodeficiency virus type 1 DNA *in vitro*. *J Virol*. 1991;65:6942-52.
21. Shoemaker C, Goff S, Gilboa E, Paskind M, Mitra SW, Baltimore D. Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: Implications for retrovirus integration. *Proc Natl Acad Sci USA*. 1980;77:3932-6.
22. Munir S, Thierry S, Subra F, Deprez E, Delelis O. Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle. *Retrovirology*. 2013;10:87.
23. Li L, Olvera JM, Yoder KE, et al. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. *EMBO J*. 2001;20:3272-81.
24. Miller MD, Wang BB, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate *in vitro*. *J Virol*. 1995;69:3938-44.
25. Kilzer JM, Stracker T, Beitzel B, Meek K, Weitzman M, Bushman FD. Roles of host cell factors in circularization of retroviral DNA. *Virology*. 2003;314:460-7.
26. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. *Retrovirology*. 2008;5:114.
27. Smith JS, Kim SY, Roth MJ. Analysis of long terminal repeat circle junctions of human immunodeficiency virus type 1. *J Virol*. 1990;64:6286-90.
28. Hong T, Drlica K, Pinter A, Murphy E. Circular DNA of human immunodeficiency virus: analysis of circle junction nucleotide sequences. *J Virol*. 1991;65:551-5.
29. Svarovskaia ES, Barr R, Zhang XC, et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase *in vivo* and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. *J Virol*. 2004;78:3210-22.
30. Randolph CA, Champoux JJ. The majority of simian immunodeficiency virus/Mne circle junctions result from ligation of unintegrated viral DNA ends that are aberrant for integration. *Virology*. 1993;194:851-4.
31. Jurriaans S, Deronde A, Dekker J, Goudsmit J, Cornelissen M. Analysis of human immunodeficiency virus type 1 LTR-LTR junctions in peripheral blood mononuclear cells of infected individuals. *J Gen Virol*. 1992;73:1537-41.
32. Julias JG, McWilliams MJ, Sarafianos SG, Arnold E, Hughes SH. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage *in vivo*. *Proc Natl Acad Sci USA*. 2002;99:9515-20.
33. Cara A, Vargas J, Keller M, et al. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. *Virology*. 2002;292:1-5.
34. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of Tcell activation and proviral integration. *EMBO J*. 1990;9:1551-60.
35. Teo IA, Morlese J, Choi JW, Shaunak S. Reliable and reproducible LightCycler qPCR for HIV-1 DNA 2-LTR circles. *J Immunol Methods*. 2002;270:109-18.
36. Yoder KE, Fishel R. PCR-based detection is unable to consistently distinguish HIV 1 LTR circles. *J Virol Methods*. 2006;138:201-6.
37. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection *in vivo*. *Virology*. 1994;205:470-8.
38. Teo IA, Choi JW, Morlese J, Taylor G, Shaunak S. LightCycler qPCR optimisation for low copy number target DNA. *J Immunol Methods*. 2002;270:119-33.
39. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. *AIDS*. 2003;17:679-83.
40. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. *Nat Med*. 2000;6:76-81.
41. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. *AIDS*. 2012;26:543-50.
42. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. *J Virol Methods*. 2012;186:68-72.
43. Brussel A, Mathez D, Broche-Pierre S, et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. *AIDS*. 2003;17:645-52.
44. Kelly J, Beddall MH, Yu DY, Iyer SR, Marsh JW, Wu YT. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. *Virology*. 2008;372:300-12.
45. Badralmaa Y, Natarajan V. Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells. *J Virol Methods*. 2013;193:184-9.
46. Malatinkova E, Kiselinova M, Bonczkowski P, et al. Accurate episomal HIV 2-LTR circles quantification using optimized DNA isolation and droplet digital PCR. *J Clin Microbiol*. 2015;53:699-701.
47. Gilliam-Ross L, Cara A, Klotman ME. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. *Viral Immunol*. 2005;18:190-6.
48. Pace MJ, Graf EH, O'Doherty U. HIV 2-long terminal repeat circular DNA is stable in primary CD4+ T Cells. *Virology*. 2013;441:18-21.
49. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. *J Virol*. 2005;79:5203-10.
50. Murray JM, Zauders JJ, McBride KL, et al. HIV DNA subspecies persist in both activated and resting memory CD4(+) T cells during antiretroviral therapy. *J Virol*. 2014;88:3516-26.
51. Clarke S, Almond N, Berry N. Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles *in vivo*. *Virology*. 2003;306:100-8.
52. Panther LA, Coombs RW, Aung SA, dela Rosa C, Gretch D, Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir *in vitro*. *J Med Virol*. 1999;58:165-73.
53. Zhu WJ, Jiao YM, Lei RY, et al. Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. *PLoS One*. 2011;6:e21081.
54. Puertas MC, Massanella M, Llibre JM, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. *AIDS*. 2014;28:325-34.
55. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. *Science*. 2000;287:646-50.
56. Thierry S, Munir S, Thierry E, et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 DNA initiate de novo integration. *Retrovirology*. 2015;12:24.
57. Fischer M, Trkola A, Joos B, et al. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection *in vivo*. *Antivir Ther*. 2003;8:97-104.
58. Delaunay C, Chareau I, Braun J, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. *AIDS*. 2010;24:2391-5.
59. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2012;59:229-35.
60. Goedert JJ, O'Brien TR, Hatzakis A, Kostrikis LG. T cell receptor excision circles and HIV-1 2-LTR episomal DNA to predict AIDS in patients not receiving effective therapy. *AIDS*. 2001;15:2245-50.
61. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. *PLoS Pathog*. 2011;7:e1001303.
62. Palmer S, Malclarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. *Proc Natl Acad Sci USA*. 2008;105:3879-84.
63. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci USA*. 1997;94:13193-7.
64. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4(+) T cells. *J Virol*. 2006;80:6441-57.
65. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4(+) T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. *J Virol*. 2009;83:8470-81.
66. Luo RT, Cardozo EF, Piovoso MJ, et al. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. *J R Soc Interface*. 2013;10:20130186.
67. Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. *Retrovirology*. 2011;8:52.
68. Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. *Clin Infect Dis*. 2014;59:1312-21.
69. Uprety P, Chadwick EG, Rainwater-Lovett K, et al. Cell associated HIV-1 DNA and RNA decay dynamics during early combination antiretroviral therapy in HIV-1-Infected Infants. *Clin Infect Dis*. 2015. [Epub ahead of print].
70. Miles LR, Agresta BE, Khan MB, Tang SX, Levin JG, Powell MD. Effect of polypyrimidine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity. *J Virol*. 2005;79:6859-67.
71. Olivares I, Sanchez-Jimenez C, Vieira CR, Toledoano V, Gutierrez-Rivas M, Lopez-Galindez C. Evidence of ongoing replication in a human immunodeficiency virus type 1 persistently infected cell line. *J Gen Virol*. 2013;94:944-54.
72. Graf EH, Texas AM, Yu JQJ, et al. Elite Suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV plus patients on and off HAART. *PLoS Pathog*. 2011;7:e1001300.
73. Buzon MJ, Seiss K, Weiss R, et al. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from Elite Controllers. *J Virol*. 2011;85:9646-50.
74. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration *in vivo*. *Nat Med*. 2001;7:631-4.
75. Casabianca A, Orlandi C, Canovari B, et al. A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients. *PLoS One*. 2014;9:e111919.
76. Vandergeerten C, Fromentin R, Merlini E, et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. *J Virol*. 2014;88:12385-96.